Literature DB >> 31591679

GSIAR: gene-subcategory interaction-based improved deep representation learning for breast cancer subcategorical analysis using gene expression, applicable for precision medicine.

Chiranjib Sur1.   

Abstract

Tumor subclass detection and diagnosis is inevitable requirement for personalized medical treatment and refinement of the effects that the somatic cells show towards other clinical conditions. The genome of these somatic cells exhibits mutations and genetic variations of the breast cancer cells and helps in understanding the characteristic behavior of the cancer cells. But their analysis is limited to clustering and there is requirement to analyze what else can be done with the data for identifying the tumor subcategory and the stages of subclasses. In this work, we have extended the work with similar data (consisting of 105 breast tumor cell lines) to solve other detection and characterization problems through computation and intelligent representation learning. Most of our work comprises of systematic data cleaning, analysis, and building prediction models with deep computational architectures and establish that the transformed data can help in better distinction of the respective categories. Our main contribution is the novel gene-subcategory interaction-based regularization (GSIAR) based data selection and analysis concept, alongside the prediction, proven to enhance the performance of the classification techniques. Graphical Abstract A graphical abstract of our model - Gene-subcategory interaction affinity-based regularization (GSIAR).

Entities:  

Keywords:  Data-driven analysis; Dual phase deep learning; Proteome (PAM50) genetic analysis; Regularized representation learning; Subcategory driven analysis

Mesh:

Substances:

Year:  2019        PMID: 31591679     DOI: 10.1007/s11517-019-02038-2

Source DB:  PubMed          Journal:  Med Biol Eng Comput        ISSN: 0140-0118            Impact factor:   2.602


  46 in total

1.  HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.

Authors:  Gabriela Paroni; Marco Bolis; Adriana Zanetti; Paolo Ubezio; Kristian Helin; Peter Staller; Lars Ole Gerlach; Maddalena Fratelli; Richard M Neve; Mineko Terao; Enrico Garattini
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

2.  Angiopoietin pathway gene expression associated with poor breast cancer survival.

Authors:  Rajesh Ramanathan; Amy L Olex; Mikhail Dozmorov; Harry D Bear; Leopoldo Jose Fernandez; Kazuaki Takabe
Journal:  Breast Cancer Res Treat       Date:  2017-01-06       Impact factor: 4.872

3.  Genes that mediate breast cancer metastasis to lung.

Authors:  Andy J Minn; Gaorav P Gupta; Peter M Siegel; Paula D Bos; Weiping Shu; Dilip D Giri; Agnes Viale; Adam B Olshen; William L Gerald; Joan Massagué
Journal:  Nature       Date:  2005-07-28       Impact factor: 49.962

Review 4.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

5.  MicroRNA gene expression deregulation in human breast cancer.

Authors:  Marilena V Iorio; Manuela Ferracin; Chang-Gong Liu; Angelo Veronese; Riccardo Spizzo; Silvia Sabbioni; Eros Magri; Massimo Pedriali; Muller Fabbri; Manuela Campiglio; Sylvie Ménard; Juan P Palazzo; Anne Rosenberg; Piero Musiani; Stefano Volinia; Italo Nenci; George A Calin; Patrizia Querzoli; Massimo Negrini; Carlo M Croce
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

6.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Authors:  Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

7.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

Authors:  Jenny C Chang; Eric C Wooten; Anna Tsimelzon; Susan G Hilsenbeck; M Carolina Gutierrez; Richard Elledge; Syed Mohsin; C Kent Osborne; Gary C Chamness; D Craig Allred; Peter O'Connell
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

Review 8.  Breast cancer prognostic classification in the molecular era: the role of histological grade.

Authors:  Emad A Rakha; Jorge S Reis-Filho; Frederick Baehner; David J Dabbs; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Andrea L Richardson; Stuart J Schnitt; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Sunil Badve; Ian O Ellis
Journal:  Breast Cancer Res       Date:  2010-07-30       Impact factor: 6.466

9.  Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.

Authors:  Robert Mechera; Savas D Soysal; Salvatore Piscuoglio; Charlotte K Y Ng; Jasmin Zeindler; Edin Mujagic; Silvio Däster; Philippe Glauser; Henry Hoffmann; Ergin Kilic; Raoul A Droeser; Walter P Weber; Simone Muenst
Journal:  BMC Cancer       Date:  2019-01-08       Impact factor: 4.430

10.  Proteogenomics connects somatic mutations to signalling in breast cancer.

Authors:  Philipp Mertins; D R Mani; Kelly V Ruggles; Michael A Gillette; Karl R Clauser; Pei Wang; Xianlong Wang; Jana W Qiao; Song Cao; Francesca Petralia; Emily Kawaler; Filip Mundt; Karsten Krug; Zhidong Tu; Jonathan T Lei; Michael L Gatza; Matthew Wilkerson; Charles M Perou; Venkata Yellapantula; Kuan-lin Huang; Chenwei Lin; Michael D McLellan; Ping Yan; Sherri R Davies; R Reid Townsend; Steven J Skates; Jing Wang; Bing Zhang; Christopher R Kinsinger; Mehdi Mesri; Henry Rodriguez; Li Ding; Amanda G Paulovich; David Fenyö; Matthew J Ellis; Steven A Carr
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.